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Abstract The Mobile Autism Risk Assessment (MARA)
is a new, electronically administered, 7-question autism
spectrum disorder (ASD) screen to triage those at highest
risk for ASD. Children 16 months–17 years (N = 222)
were screened during their first visit in a developmental-
behavioral pediatric clinic. MARA scores were compared
to diagnosis from the clinical encounter. Participant med-
ian age was 5.8 years, 76.1 % were male, and most par-
ticipants had an intelligence/developmental quotient score
[85; 69 of the participants (31 %) received a clinical
diagnosis of ASD. The sensitivity of the MARA in
detecting ASD was 89.9 % [95 % CI = 82.7–97]; the
specificity was 79.7 % [95 % CI = 73.4–86.1]. In a high-
risk clinical setting, the MARA shows promise as a screen
to distinguish ASD from other developmental/behavioral
disorders.
Keywords Autism screening  Autism detection 
Machine learning  Clinical validation
Introduction
Autism spectrum disorder (ASD) is characterized by sig-
nificant impairments with social skills and communication,
and atypical or repetitive behaviors (American Psychiatric
Association and Task Force on DSM-IV 1994; Association
2013). The diagnosis is made clinically based on criteria
described in the Diagnostic and Statistical Manual of
Mental Disorders (DSM) (American Psychiatric Associa-
tion and Task Force on DSM-IV 1994; Association 2013).
Standardized assessment tools can be used to help opera-
tionalize the DSM criteria (Johnson and Myers 2007). ASD
is reported to occur in up to 1 in 68 children (‘‘Prevalence
of autism spectrum disorder among children aged
8 years—autism and developmental disabilities monitoring
network, 11 sites, United States, 2010, 2014‘‘); thus, it
represents a major public health issue. Although parents of
children with ASD often report developmental concerns by
the ages of 12–18 months, the average age of diagnosis in
the United States is around 4 years (Zwaigenbaum et al.
2009). Screening tools can help to prioritize children at
highest risk of ASD. Identifying those at highest risk may
help facilitate more timely diagnostic assessments and
access to evidence-based behavioral interventions, which
have been shown to improve developmental and functional
outcomes (Dawson et al. 2010; National Research Council
(U.S.). Committee on Educational Interventions for Chil-
dren with Autism 2001).
Screening tools can be used to detect normal develop-
ment from abnormal development (Level 1) and, when
developmental delays are suspected, to detect ASD from
other developmental or behavioral conditions (Level 2)
(Johnson and Myers 2007). With the relatively high
prevalence of ASD, the use of Level 2 ASD screening tools
to appropriately triage those who need more urgent
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diagnostic clarification is important. Several current Level
2 screening tools exist for detecting ASD (Norris and
Lecavalier 2010) although most take considerable time to
administer and require scoring to interpret (Johnson and
Myers 2007). Some Level 2 screening tools, such as the
Screening Tool for Autism in Two-Year-Olds (STAT)
(Stone et al. 2008) and Autism Detection in Early Child-
hood (ADEC) (Nah et al. 2014), require the clinician to
directly observe the child’s behavior while others, such as
the Social Responsiveness Scale (SRS) (Constantino 2002),
the Social Communication Questionnaire (SCQ) (Rutter
et al. 2003), and Gilliam Autism Rating Scale-Second
Edition (GARS-2) (Gilliam 2006) rely solely on parent
report. While eliminating clinician observation time may
be an advantage, the validity of parent report measures is
dependent on how well the items assessed align with
diagnostic criteria, and this can be influenced by the child’s
age, developmental/intellectual level, and language abili-
ties (Hampton and Strand 2015; Oosterling et al. 2010).
The SRS (Constantino 2002) is a 65-item rating scales
validated to distinguish ASD from other developmental
conditions among children ages 4–18 years old (Con-
stantino et al. 2000, 2003). Based on parent or teacher
responses to the questions about symptoms of autism, a
single score is generated, with higher score indicative of
higher risk of the child having autism. The SCQ (Rutter
et al. 2003) is another screening tool to discriminate
between ASD cases and non-ASD cases in preschool and
school-aged children. The SCQ consists of 40 yes/no
questions that are based on the Autism Diagnostic Inter-
view-Revised (ADI-R), which is a lengthy, parent inter-
view that must be administered by a trained clinician (Lord
et al. 1994). Questions remain regarding the optimal
scoring threshold for the SCQ and whether some items
should be adjusted based on the child’s language level
(Eaves et al. 2006). Additionally, the performance of the
SCQ when used to identify toddlers with ASD versus other
developmental issues is greatly influenced by IQ, with
sensitivity of 0.35 and specificity of 0.63 for toddlers with
IQ[ 90 (Oosterling et al. 2010). The GARS-2 (Gilliam
2006) is a 42-item parent questionnaire to screen for ASD
among individuals 3–22 years of age. While psychometric
properties have not yet been independently published for
the second edition GARS (GARS-2), four of the five
studies pertaining to the original GARS (Gilliam 1995)
evaluated in a recent meta-analysis (Hampton and Strand
2015) found the GARS to have sensitivity and specificity
levels below 70–80 %.
The current study sought to test a newly developed
parent/caregiver completed Level 2 ASD screening tool,
the Mobile Autism Risk Assessment (MARA). The MARA
is brief and administered via an electronic platform with
automatic scoring, thus decreasing barriers related to
clinician training and time to score. Similar to the SCQ, the
MARA stemmed from analysis of score sheets from the
ADI-R but rather than clinical impression, machine learn-
ing techniques were employed to create this screener.
Complete sets of answers to the ADI-R from the Autism
Genetic Resource Exchange (AGRE) on 891 autism cases
and 75 non-autism controls were used to build a series of
classifiers from a set of different machine learning algo-
rithms. The algorithm that performed the best was then
independently validated using data from the Simons
Foundation and the Boston Autism Consortium and it
correctly identified a total of 1974 out of 1975 autistic
cases (Wall et al. 2012). Although these results are
promising, the MARA has not been studied prospectively,
in a clinical setting, with a control sample of children with
developmental disorders other than ASD. The primary
objective of the current study is to test the sensitivity and
specificity of the MARA in a clinical sample of children
referred for developmental/behavioral concerns.
Methods
Setting and Participants
This study was conducted in the developmental-behavioral
pediatrics clinic of a large academic medical center. Par-
ticipants were children, ages 16 months–17 years, sched-
uled for their first diagnostic consultation visit to see a team
of clinicians including a developmental- behavioral pedi-
atrician and child psychologist, from November 2012
through December 2013. Referrals are generally made
from pediatricians, early intervention agencies, school
districts, and self-referrals. To obtain an appointment for a
child, the guardian must complete paperwork stating the
concerns and information about medical and developmen-
tal history and all those who complete this intake paper-
work are scheduled for a clinic appointment; there is no
screening process to deny visits. Children and adolescents
are assigned to consultation clinic visits based on their age,
rather than being assigned based on their referral concerns.
The clinic population comes primarily from within the state
of Massachusetts (86 %), with 9 % of those seen from
other states within the United States and 5 % from other
countries. Insurance type in the clinic is as follows: 60 %
private, 37 % public, and 3 % self-pay. Whenever possible,
caregivers were informed of the study via letter and a
phone call prior to the clinic visit. Caregivers were directed
to a secure website on which they could give electronic
consent and complete the MARA. Initially recruitment was
completed through letter and phone call only, but this
method resulted in low enrollment numbers. Therefore,
beginning 2 months after study initiation, a research
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assistant also approached caregivers in the waiting room
prior to the beginning of the clinical visit and provided an
iPad on which they could complete the MARA. Although
financial compensation was not provided, as appreciation
for completing the study all participating caregivers were
entered into a raffle for the chance to receive an iPad. Non-
English speaking caregivers were excluded given that the
MARA questions are currently only available in English.
This study received Institutional Review Board approval.
Study and Clinical Measures
The MARA is a 7-item parent questionnaire about a
child’s communication, social skills, and behaviors
(Table 1). Each question has several accompanying sen-
tences that the caregiver can consider in formulating
answer choices. There are 4–5 answer choices available
for each question, as well as the option of ‘‘not applica-
ble’’. Caregivers could complete the screener electroni-
cally on an iPad, computer, or any other device connected
to the Internet. The set of answers is run through a
machine learning model that uses an alternating decision
tree algorithm to generate a total score (ranging from -10
to 7). This model was trained on 891 autism cases and 75
non-autism controls from the Autism Genetic Resource
Exchange (AGRE) (Geschwind et al. 2001) repository and
independently tested on archived samples from the Simons
Simplex Collection and from the Boston Autism Consor-
tium (Wall et al. 2012). The model used to train the
classifier was an alternating decision tree. This approach
finds features, in this case autism behaviors measured by
ADI-R, that predict known class values, i.e. a person
diagnosed with autism versus a person who was assessed
and determined not to have autism. The power of the
prediction was measured in terms of the number of cor-
rectly classified individuals during the training procedure,
maximizing both precision and recall. The classifier was
constructed using 10-fold cross validation, in which the
data were divided evenly into 10-folds, and 90 % of the
data (nine-folds) were dedicated to model training and the
remaining 10 % (one-fold) was used to test the accuracy of
the model. This process was repeated 10 times, until all
combinations of training and testing folds had been
exhausted. This resulted in a final classifier—a decision
tree consisting of a collection of alternating prediction
nodes and test nodes. The test nodes check whether a
certain condition is true or not, for example whether a
child scores high or low on a particular behavior. The
predictor node predicts the likelihood of either an autism
or non-autism classification. Classification is then
achieved by summing the contributions from predictor
nodes of all paths that an instance—in this case a set of
data for a new child being screened—traverses.
The decision tree algorithm used for the MARA con-
tains 7 total elements (the questions in the MARA) and 20
decision nodes (the answers to the questions, some of
which have been collapsed together) that either increase
or decrease the total score depending on the answer pro-
vided by a parent or caretaker when taking the MARA.
The outcome of either autism spectrum disorder or non-
autism spectrum disorder is provided by the alternating
decision tree by following all paths in the tree for which
all decision nodes are true and summing the values. If the
final score is negative, the instance is classified as autism
spectrum disorder; if positive the instance is classified as
non-autism spectrum disorder. Figure 1 depicts a repre-
sentation of the decision tree classification system for the
MARA. The magnitude of the score is a measure of
confidence in the classification, such that values closer to
0 have lower confidence than values closer to the
extremes of the distribution, a property of the alternating
decision tree model (Wall et al. 2012). The MARA is
written at a 7.9 grade reading level and takes about 5 min
to complete.
Each subject participated in a multidisciplinary team
clinic visit conducted by developmental-behavioral pedia-
tricians and child psychologists, as per the routine for
initial assessment in this clinic setting. The visit consisted
Table 1 Mobile autism risk assessment (MARA) questions
1. How well does your child understand spoken language, based on speech alone? (Not including using clues from the surrounding
environment)
2. Can your child have a back-and-forth conversation with you?
3. Does your child engage in imaginative or pretend play?
4. Does your child play pretend games when with a peer? Do they understand each other when playing?
5. Does your child maintain normal eye contact for his or her age in different situations and with a variety of different people?
6. Does your child play with his or her peers when in a group of at least two others?
7. When were your child’s behavioral abnormalities first obvious?
The behaviors measured by these 7 questions were identified from analysis of ADI-R score sheets using a decision tree learning model
(Wall et al. 2012)
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of collection of complete medical and developmental his-
tory, physical examination, administration of develop-
mental or cognitive measures, most commonly the Bayley
Scales of Infant and Toddler Development, Third Edition
(Bayley 2006), Differential Ability Scales, Second Edition
(Elliott 2007) or the Wechsler Intelligence Scales for
Children, Fourth Edition (Wechsler 2003), and behavior
and/or adaptive functioning measures, such as the Vineland
Adaptive Behavior Scales, Survey Interview Form (Spar-
row et al. 1984). The Autism Diagnostic Observation
Schedule (ADOS) was administered if an autism spectrum
disorder was a diagnostic consideration in the clinical
opinion of the team members or a significant concern of the
caregivers. The decision of which tests to administer, and
whether or not to administer the ADOS, was made either
right before the clinical visit or during the course of the
visit. After discussion of the results of the above-mentioned
measures, clinical diagnoses were made by consensus
agreement between the clinicians. During the study period,
the updated Diagnostic and Statistical Manual of Mental
Disorders-Fifth Edition (DSM-5) was published, with
changes in diagnostic criteria for ASD. It is reasonable to
assume that clinicians may have primarily conceptualized
the DSM-IV-TR model for ASD in the first half of the
study, and began to conceptualize the DSM-5 model for
ASD once it was published in May 2013, which was mid-
way through this study. Clinicians completed checklists
assessing both the Diagnostic and Statistical Manual of
Mental Disorders-Fourth Edition (DSM-IV-TR) and the
new DSM-5 criteria for 62 % of the total sample because
collection of these checklists was implemented as a Quality
Improvement project that occurred concurrently with this
study. In all cases, clinicians were blind to the results of the
study screener to ensure that the clinical diagnoses and
study screener results were independent. The ADI-R was
not used for any of the clinical encounters, and is not
routinely used in this clinical setting, thus eliminating
possible confounding that could have occurred from using
a screening tool which was developed from a diagnostic
instrument administered to study participants (the ADI-R).
Results of the clinical evaluation, including results of
developmental or cognitive measures, verbal status, and
clinical diagnoses made, were abstracted from the medical
record.
Data Analysis
Descriptive data about the sample were calculated using
frequencies, t tests and Chi square values with accompa-
nying p values. Chi square analyses were used to determine
if the screener performed differently in those with ASD
versus those without. Sensitivity and specificity were cal-
culated to determine how well the screener performed, both
in the whole sample and separately for different ages and
developmental/cognitive abilities. Sensitivity was calcu-
lated as the proportion of all participants given a clinical
ASD diagnosis who screened positive for ASD. Specificity
was calculated as the proportion of all participants not
given a clinical ASD diagnosis who screened negative for
ASD. The positive predictive value was calculated as the
likelihood that a person with a MARA result indicative of
ASD actually received a clinical ASD diagnosis. The
negative predictive value was calculated as the likelihood
that a person with a MARA result negative for ASD did not
actually receive a clinical ASD diagnosis.
Results
Descriptive Results
A total of 222 participants completed the MARA and then
participated in the clinical visit, representing 46 % of those
invited to participate in the study. This relatively low
Fig. 1 Representation of the MARA Algorithm. The alternating
decision tree algorithm used for the MARA contains 7 total elements
and 20 decision nodes. The outcome of either autism spectrum
disorder or non-autism spectrum disorder is provided by the
alternating decision tree by following all paths in the tree for which
all decision nodes are true and summing the values. The numbers
shown in the decision nodes are approximations of the fractional
values contained in the algorithm
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enrollment rate reflects the low yield of the initial
recruitment strategy (i.e. mail contact) employed in the
initial 2 months of the study. Given the resulting low
enrollment rate, we changed to in-person recruitment in the
clinic waiting room (rather than relying on subjects par-
ticipating remotely prior to their clinical encounter) with a
much improved enrollment rate. The majority of subjects
(N = 213; 95.95 %) were enrolled via in-person recruit-
ment; 6 subjects (2.7 %) were enrolled via letter and phone
call recruitment efforts, and only 3 subjects (1.3 %) were
enrolled via letter recruitment efforts alone. There was no
significant difference in median age, gender, or receipt of a
clinical ASD diagnosis between those who participated and
those who did not. The median age of participants was
5.8 years, 76.1 % were male, and 66.7 % of those with
non-verbal IQ data available in the medical record
(n = 117) had a non-verbal cognitive score [85. For the
remaining subjects (N = 105), standardized scores were
not reported or full developmental/cognitive testing was
not completed, most commonly because it had been com-
pleted elsewhere within the past year, there was a need to
focus on other assessments, or insurance did not cover full
testing. For subjects who had data about verbal status
abstracted from the medical record (N = 215), 198 sub-
jects were verbal and 17 subjects were non-verbal. For 31
subjects caregivers reported an existing ASD diagnosis
prior to the multidisciplinary team consultation. Of all
participants, 69 (31 %) were given a clinical diagnosis of
an autism spectrum disorder and the remaining 153 were
given other clinical diagnoses (such as Attention Deficit
Hyperactivity Disorder and Speech Delay/Language
Disorder). Figure 2 shows the distribution and overlap of
the seven most frequently identified diagnostic categories
in our sample. Participants who were given a clinical ASD
diagnosis were more likely to be male, younger age, and
have intellectual or developmental delays compared to
those given other clinical diagnoses (Table 2). The Autism
Diagnostic Observation Schedule (ADOS) was adminis-
tered in 67 of the 69 cases in which a clinical ASD diag-
nosis was made and, in all of these cases, supported the
clinical ASD diagnosis. The ADOS was not administered
to 2 children given a clinical diagnosis of ASD based on
clinician judgment that the child would not tolerate the
testing or there was not sufficient time to complete it. For
50 subjects, clinicians recorded which DSM-IV-TR sub-
group diagnosis was given as follows: 86 % Autistic
Disorder, 12 % Pervasive Developmental Disorder, not
otherwise specified, 2 % Asperger’s Disorder. For the
remaining 19 subjects, the clinical diagnosis was recorded
as ‘‘autism spectrum disorder’’ with no DSM-IV-TR sub-
type identified. Of the 69 participants given a clinical ASD
diagnosis, 50 had information available about specific
criteria met on both DSM-IV-TR and DSM-5 criteria and
92 % met criteria for ASD under both sets of criteria.
During the course of this study the new DSM-5 criteria
were released.
Performance of the MARA
MARA scores were dichotomized to be high or low risk for
ASD based on previously established cut-offs (Wall et al.
2012). The MARA scores in this study ranged from -9.28
to 6.43, with negative scores indicating high risk and
positive scores suggesting low risk for ASD. Subjects who
received a clinical ASD diagnosis were more likely than
those without a clinical ASD diagnosis to receive a MARA
score that was indicative of ASD (x2 = 91.77, p\ 0.0001).
Overall, the sensitivity of the MARA in detecting ASD was
89.86 %, 95 % CI [82.7, 97.0] and the specificity was
79.74 %, 95 % CI [73.4, 86.1]. Table 3 demonstrates the
performance of the MARA across different ages and dif-
ferent developmental/cognitive abilities, showing a higher
specificity for those with cognitive/developmental scores
that were in the low average range or higher (C85). Among
subjects who were non-verbal (N = 17) the MARA had a
high sensitivity (1.0) for detecting ASD, but misclassified 3
out of the 4 non-verbal subjects as having ASD
Fig. 2 Diagnosis overlap network across our clinical sample.
Network visualization of diagnoses across our clinical sample
(n = 222). Outer grey nodes represent individual subjects in our
sample and inner colored nodes represent the seven major diagnostic
categories observed. Edges connecting inner nodes to outer nodes
indicate that subject received that diagnosis. Outer nodes with
multiple connections indicate subjects with multiple comorbid
diagnoses. 10 subjects in our sample did not receive any diagnoses
in these seven major categories, but may have received other less
common diagnoses (Color figure online)
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(specificity = 0.25). For the total sample, the positive
predictive value was 0.67 and the negative predictive value
was 0.95. Although the subjects in the study were those
being seen for a multidisciplinary diagnostic consultation
there were 31 subjects for whom caregivers reported an
existing ASD diagnosis prior to receiving the results of the













Male 169 (76.1 %) 60 (87.0 %) 109 (71.2 %) 0.018
Age in years
Median (IQR) 5.8 (4.6) 3.9 (3.3) 6.6 (3.9) \0.00011
Other clinical diagnoses
ADHD, any sub-type 58 (26.13 %) 1 (1.4 %) 57 (37.2 %) \0.0001
Speech delay/language disorder 59 (26.58 %) 4 (5.8 %) 55 (36.0 %) \0.0001
Developmental coordination disorder 43 (19.36 %) 7 (10.1 %) 36 (23.5 %) 0.0314
Learning disorder 42 (18.92 %) 2 (2.9 %) 40 (26.1 %) \0.0001
Mood disorder 2 (0.90 %) 0 2 (1.3 %) 0.8519
Depression 5 (2.25 %) 0 5 (3.3 %) 0.3029
Anxiety disorder 33 (14.86 %) 3 (4.3 %) 30 (19.6 %) 0.0059
Hearing or vision impairment 3 (1.35 %) 1 (1.4 %) 2 (1.3 %) 0.9324
Genetic condition 6 (2.70 %) 2 (2.9 %) 4 (2.6 %) 0.9038
Global developmental delay/intellectual disability 24 (10.81 %) 20 (29.0 %) 15 (9.8 %) 0.0006
Other medical condition 78 (35.14 %) 13 (18.8 %) 65 (42.5 %) 0.0011
Developmental/IQ scorea
Median (IQR)
Full Scale IQ 97.0 (22.0) 96.0 (30) 97.5 (20.8) 0.62121
Non-verbal IQ 91.0 (22.0) 87.5 (20.8) 95.0 (19.0) 0.09141
Verbal IQ 94.0 (24.0) 87.0 (36.5) 96.0 (21.3) 0.09961
* Chi square was test statistic used unless otherwise indicated
1 Wilcoxon rank-sum test used to assess for differences in groups
a Developmental/IQ score had some missing data; N = 105 subjects had Full Scale IQ data, N = 117 subjects had non-verbal IQ data, N = 129
subjects had verbal IQ data available
ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, IQR interquartile range, IQ intelligence quotient
Table 3 Performance of the MARA across different ages and cognitive/developmental levels
# Subjects # Subjects with clinical ASD diagnosisa Sensitivity
[95 % CI] (%)
Specificity
[95 % CI] (%)
Total sample 222 69 89.9 [82.7–97] 79.7 [73.4–86.1]
Age\3 years 38 25 96 [88.3–100] 61.5 [35.1–88]
Age 3–6 years 103 33 84.8 [72.6–97.1] 75.7 [65.7–85.8]
Age[6 years 81 11 90.9 [73.9–100] 87.1 [79.3–95]
Cognitive/development scorea\70 15 7 100 [100–100] 62.5 [29–96]
Cognitive/development scorea 70–84 24 14 78.6 [57.1–100] 50 [19–81]
Cognitive/development scorea 85–100 46 19 100 [100–100] 70.4 [53.1–87.6]
Cognitive/development scorea[100 32 12 75 [50.5–99.5] 80 [62.5–97.5]
a Cognitive/development score is based on non-verbal IQ for whom N = 117 subjects had available data
MARA Mobile Autism Risk Assessment
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diagnostic consultation. Therefore, in a post hoc analysis
we excluded these subjects and among the 191 remaining
subjects the MARA performed with sensitivity of 89.58 %
and specificity of 80.42 %. As an additional post hoc
analysis, we evaluated whether the performance of the
screener varied based on whether the caregiver completed
it at home or in the clinic and we did not see any difference
in screening performance based on location of completion
(x2 = 5.63, p = 0.13).
There were 31 subjects who screened positive for ASD
but were not given a clinical diagnosis of ASD. The most
common clinical diagnoses for these subjects were Lan-
guage Delay/Disorder (48.4 %), Motor Delay/Coordination
Disorder (38.7 %), and Global Developmental Delay/In-
tellectual Disability (25.8 %). There was no significant
difference in IQ between the correctly classified and mis-
classified groups (p = 0.8304). Misclassified subjects were
more likely to be diagnosed with a language delay/disorder
compared to correctly classified subjects (44.7 vs. 22.9 %;
p = 0.01). There were 7 subjects who screened negative
for ASD but were given a clinical diagnosis of ASD. These
subjects all had an IQ C 84 and most had MARA scores
that were close to the cut-off for ASD; specifically, 5 had a
fairly low score (\3) on the MARA. Figure 3 shows a
histogram of the MARA scores for ASD and non-ASD
diagnoses.
Discussion
The current study demonstrates that the MARA autism
screener performs well (sensitivity = 89.9 % and speci-
ficity = 79.7 %) in detecting children likely to receive a
clinical diagnosis of ASD among those referred to a tertiary
care center for developmental or behavioral concerns.
When tested among 222 subjects, with a range of different
ages (median age = 5.8 years) and abilities, the MARA
performed best for subjects with an IQ of 85 or higher.
In its current form, the MARA is considered a Level 2
screening tool, meaning that it is meant to differentiate
between children at risk for ASD and other developmental
disorders. When compared to several other ASD specific
Level 2 caregiver questionnaire screeners in use (Johnson
and Myers 2007), the MARA has comparable or superior
ability to detect ASD among children with developmental
or behavioral concerns. Of currently available Level 2 ASD
rating scales, the Social Communication Questionnaire
(SCQ) (Rutter et al. 2003) has been most extensively
studied (Norris and Lecavalier 2010). The SCQ is reported
to be able to discriminate between ASD cases and non-
ASD cases with 88 % sensitivity and 72 % specificity
(Chandler et al. 2007) although it is reported to have lower
sensitivity and specificity for detecting ASD in pre-school
aged children (Eaves et al. 2006). The Social Respon-
siveness Scale (SRS) (Constantino 2002) is a commonly
used parent report measure to assess likelihood of ASD and
it is reported to have sensitivity ranging from 75 to 95 %
and specificity ranging from 8 to 96 % (Hampton and
Strand 2015). The Gilliam Autism Rating Scale (GARS)
(Gilliam 1995) is another commonly used parent measure
of ASD, despite sensitivity reported to be 37–79 % and
specificity reported to be only 54–68 % (Hampton and
Strand 2015). The great range in reported sensitivities and
specificities for different screening tools is likely in part
attributable to different sample compositions, as screeners
may perform differently for different ages, and for those
with different developmental/cognitive abilities (Hampton
and Strand 2015; Oosterling et al. 2010). Therefore, further
studies assessing the MARA will include larger sample
sizes to allow for more informative psychometric infor-
mation about how the MARA performs among children
and adolescents of differing ages and with differing
developmental presentations. If it is found to perform well
in a larger validation study, the MARA may be particularly
useful in secondary screening efforts since it is adminis-
tered via an electronic platform with automatic scoring that
decreases clinician training needed to implement, and
increases potential ability for dissemination as it can easily
be completed remotely. However, the need for electronic
scoring could potentially be seen as a disadvantage so
Fig. 3 MARA score distribution. This histogram shows the distribu-
tion of MARA scores for those with ASD compared to those without
ASD. The line at 0 represents the classification cutoff for the MARA
algorithm—individuals with a MARA score\0 are classified as ASD
and individuals with a MARA score [0 are classified as non-ASD
using this screener
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future studies will need to evaluate the feasibility of
implementation of the MARA across diverse clinical
settings.
Although the MARA stemmed from analysis of score
sheets from the Autism Diagnostic Interview-Revised
(Lord et al. 1994) it is not meant to replace a diagnostic
encounter. Instead, if our findings are replicated in larger
clinical samples, the MARA could serve as a triage tool to
help identify children with developmental and/or behav-
ioral concerns that are highest risk for meeting criteria for
ASD in order to expedite their diagnostic evaluation and
receipt of behavioral interventions. Our results show that
those who were misclassified by the MARA as high like-
lihood for ASD (but not given a clinical ASD diagnosis)
were most often diagnosed with language delays or disor-
ders, which is not surprising given the clinical overlap that
often exists between children with ASD versus language
delays or disorders. Of the 7 subjects who were ‘‘missed’’
by the screener, most were fairly close to the cut-off for
ASD (5 of the subjects had a MARA score\3) and would
be flagged as challenging cases requiring more extensive
assessment in clinical implementation of this screening
measure.
Although the preliminary findings of the psychometric
properties of the MARA in a clinical setting are encour-
aging, these findings are not as robust as those initially
reported in the pilot study run on archival samples (Wall
et al. 2012). The pilot focused on construction of a clas-
sifier optimized for performance with classifying autism
spectrum disorder from controls. This study had several
limitations, most importantly including the high prevalence
of classic, DSM-IV Autistic disorder in the archival sam-
ples used for validation and the lack of testing on children
with other forms of autism spectrum disorder (e.g. PDD-
NOS) or with developmental delays other than autism
spectrum disorder. Therefore the drop in accuracy, in
particular the decline in specificity exhibited here, is
expected given the large proportion of children in our study
with developmental delays other than autism spectrum
disorder. Additionally, in the prior pilot study (Wall et al.
2012), the data were obtained through results of clinical
ADI-R interviews administered by trained interviewers
whereas, in the current study, the data were obtained
through parental responses, and thus a discrepancy in
responses in the different studies may be expected.
The findings of our study must be considered in the
context of some potential limitations. Our study was con-
ducted at only one large academic medical center, thus
potentially limiting generalizability of the results. How-
ever, evaluating the MARA in a high risk setting that
specializes in evaluating children with a range of devel-
opmental and behavioral concerns enabled us to test the
specificity of the MARA in detecting ASD versus other
developmental conditions. Future studies should evaluate
the MARA across diverse clinical settings. This study was
conducted at the time of transition between DSM-IV-TR
and DSM-5 ASD criteria. Although specific information
collected for a subset of patients did not reveal significant
variation in diagnostic outcomes based on use of DSM-IV-
TR versus DSM-5 criteria, it is possible that the change in
criteria will result in some changes in diagnostic practice.
Thus, future studies that occur once DSM-5 criteria are
fully operationalized in clinical practice will be important.
Additionally, information was not available on how the
changing DSM criteria may have influenced comorbidities
in the sample. For those who were not diagnosed with
ASD, several other clinical diagnoses were made, most
commonly ADHD, speech delay/language disorder, learn-
ing disorders, and other medical conditions. The hetero-
geneity in clinical diagnoses given has important
implications for interpretation of specificity (i.e., differen-
tiating ADHD or speech delay/language disorder from
ASD is more challenging than differentiating learning
disorder or other medical conditions from ASD) thus future
studies can further assess the specificity of the MARA in a
more diagnostically homogeneous clinical population.
Nonetheless, in this initial study the performance of the
MARA performed sufficiently to warrant further evaluation.
In assessing the performance of the MARA in different
groups based on cognitive/developmental level and age,
small sample sizes in some groups warrant cautious inter-
pretation. In particular, there were relatively few participants
in this study with developmental/IQ level \70 (N = 15
participants) and there were also relatively few young par-
ticipants (N = 38 participants less than 3 years old).
Although the sensitivity was high in these groups, specificity
was relatively low and larger sample sizes must be studied
as a next step. Additionally, the ASD and non-ASD groups
differ significantly on both age and percentage with devel-
opmental/intellectual delays and these differences limit the
interpretation of the sensitivity and the specificity. The rel-
atively large percentage of subjects with missing develop-
ment/IQ scores reported also limits the interpretation of
these findings. Future studies can further investigate if the
MARA performs more robustly for certain ages and/or
cognitive/developmental levels. We were not able to obtain
specific information about the socioeconomic status of par-
ticipants in this study, although information about the
insurance status are known for the clinic in general and
reported in the methods section. Despite these limitations,
our findings support further evaluation of the MARA for
potential widespread dissemination as a secondary screener
to assess developmental concerns if it continues to perform
well in larger, diverse clinical samples.
When tested in a clinical sample of 222 subjects with
median age of 5.8 years and most with intact cognitive
1960 J Autism Dev Disord (2016) 46:1953–1961
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abilities (cognitive/developmental score [85), this new
ASD screening tool (the MARA) demonstrated good
ability to distinguish ASD versus other developmental and
behavioral concerns. The electronic platform, brief
administration time and automatic scoring increase its
potential for widespread use as a secondary ASD screening
tool if further studies support these findings.
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